What non‑controlled‑substance medication can be prescribed for insomnia, and should risperidone be administered in the morning rather than at night?

Non-Controlled Substance Medications for Insomnia

For insomnia treatment without controlled substances, prescribe either low-dose doxepin (3-6 mg) for sleep maintenance problems or ramelteon (8 mg) for sleep onset difficulties, as these are the only non-controlled options with guideline support from the American Academy of Sleep Medicine. 1

Evidence-Based Non-Controlled Options

The 2017 AASM guidelines provide clear recommendations for non-controlled medications:

Recommended Agents:

• Doxepin (3-6 mg): Suggested for sleep maintenance insomnia. This is a low-dose formulation specifically for insomnia, far below antidepressant doses 1
• Ramelteon (8 mg): Suggested for sleep onset insomnia as a melatonin receptor agonist 1
• Suvorexant: An orexin receptor antagonist suggested for sleep maintenance, though it is a newer controlled substance in some jurisdictions 1

Agents NOT Recommended:

The guidelines explicitly recommend against several commonly used options:

• Trazodone (50 mg): Not recommended despite widespread off-label use 1
• Diphenhydramine: Not recommended 1
• Melatonin (2 mg): Not recommended 1
• L-tryptophan: Not recommended 1

This is critical because trazodone remains one of the most commonly prescribed off-label medications for insomnia, yet lacks evidence support and carries significant risks including orthostatic hypotension and cardiac arrhythmias 2, 3.

Risperidone Timing Question

Risperidone should be administered at bedtime, not during the daytime, when used for its approved indications. 4

Key Points About Risperidone:

• Not indicated for insomnia: Risperidone is FDA-approved only for schizophrenia, bipolar mania, and irritability associated with autism—not for primary insomnia 4

• Somnolence is a side effect: The FDA label specifically states that "patients experiencing persistent somnolence may benefit from a once-daily dose administered at bedtime" 4. This acknowledges that sedation is an adverse effect, not a therapeutic benefit for sleep

• Timing evidence: Research shows that even when risperidone 1 mg was given in the morning (15 hours before bedtime), it still decreased REM sleep and increased stage 2 sleep, demonstrating persistent sedative effects 5

Clinical Caution:

Using antipsychotics like risperidone off-label for insomnia is not recommended due to:

• Lack of efficacy data for insomnia disorder
• Significant metabolic risks (weight gain, diabetes, dyslipidemia)
• Extrapyramidal symptoms
• Increased mortality risk in elderly patients with dementia
• No guideline support for this indication 2, 3

Practical Algorithm

For sleep onset insomnia:

1. First-line: Ramelteon 8 mg at bedtime 1
2. Alternative: Consider short-acting Z-drugs if controlled substances are acceptable 2

For sleep maintenance insomnia:

1. First-line: Doxepin 3-6 mg at bedtime 1
2. Alternative: Suvorexant (if available and acceptable) 1, 3

For both sleep onset and maintenance:

• Doxepin may provide benefit for both, though primarily studied for maintenance 3

Avoid entirely for primary insomnia:

• Trazodone (despite common use)
• Antihistamines
• Antipsychotics including risperidone
• Over-the-counter melatonin supplements